Trials / Completed
CompletedNCT00159731
Safety of Pregabalin in the Treatment of Pain Due to Diabetic Peripheral Neuropathy
An Open Label Extension Safety Trial of Pregabalin (CI-1008) in Subjects With Diabetic Peripheral Neuropathy
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 160 (planned)
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to 1) provide continued pregabalin treatment for 6 additional months to patients who have taken part in the placebo controlled study A0081060; and 2) find out if pregabalin is safe at a dose of 600 mg/day (taken twice a day)
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Pregabalin |
Timeline
- Start date
- 2005-01-01
- Completion
- 2006-05-01
- First posted
- 2005-09-12
- Last updated
- 2021-01-22
Locations
29 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00159731. Inclusion in this directory is not an endorsement.